Researches

Displaying 391 - 400 of 4023
# Title Department Research Year
391 New 1, 3, 4‐oxadiazoles linked with the 1, 2, 3‐triazole moiety as antiproliferative agents targeting the EGFR tyrosine kinase Department of Pharmaceutical Organic Chemistry 2022
392 New 1,2,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization Department of Pharmaceutical Organic Chemistry 2022
393 New 1,2,4-oxadiazole/pyrrolidine hybrids as Topoisomerase IV and DNA gyrase inhibitors with promising antibacterial activity 2022
394 New 1,3,4-Oxadiazole-Chalcone/Benzimidazole Hybrids as Potent Anti-proliferative Agents Department of Pharmaceutical Organic Chemistry 2022
395 New Cell Cycle Checkpoint Pathways Regulators with 2-Oxo-indoline Scaffold as Potential Anticancer Agents: Design, Synthesis, Biological Activities and In Silico Studies Department of Medicinal Chemistry 2022
396 New Insights into the Structural Requirements of Isatin-Derived Pro-Apoptotic Agents against Acute Myeloid Leukemia Department of Medicinal Chemistry 2022
397 New pyrimidine/thiazole hybrids endowed with analgesic, anti-inflammatory, and lower cardiotoxic activities: Design, synthesis, and COX-2/sEH dual inhibition Department of Pharmaceutical Organic Chemistry 2022
398 Novel Azine Linked Hybrids of 2-indolinone and Thiazolodinone Scaffolds as CDK2 Inhibitors with Potential Anticancer Activity: In Silico Design, Synthesis, Biological, Molecular Dynamics and Binding Free Energy Studies Department of Medicinal Chemistry 2022
399 Novel indazole derivatives as potent apoptotic antiproliferative agents by multi-targeted mechanism: Synthesis and biological evaluation Department of Pharmaceutical Organic Chemistry 2022
400 Novel piperine-carboximidamide hybrids: design, synthesis, and antiproliferative activity via a multi-targeted inhibitory pathway Department of Pharmaceutical Organic Chemistry 2022